Results 81 to 90 of about 174,356 (352)

Unraveling the Molecular Mechanisms of Glioma Recurrence: A Study Integrating Single‐Cell and Spatial Transcriptomics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Glioma recurrence severely impacts patient prognosis, with current treatments showing limited efficacy. Traditional methods struggle to analyze recurrence mechanisms due to challenges in assessing tumor heterogeneity, spatial dynamics, and gene networks.
Lei Qiu, Yinjiao Fei, Jiaxuan Ding, Kexin Shi, Jinyan Luo, Yuchen Zhu, Xingjian Sun, Gefei Jiang, Yuandong Cao, Weilin Xu, Shu Zhou   +10 more
wiley   +1 more source

Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report

Case Reports in Oncology, 2019
Hairy cell leukemia (HCL) is rare type of leukemia. This neoplasm is well-known to present with pancytopenia and splenomegaly. HCL is associated with BRAF mutation in 100% of cases.
Shehab F. Mohamed, Feryal Helmi, Susanna El-Akiki, Halima El Omri, Abdulqadir Nashwan, Mohamed A. Yassin   +5 more
doaj   +1 more source

The role of autophagy in the thyroid tumors development, connection with the AKT/m-TOR signaling pathway activation

Клиническая и экспериментальная тиреоидология, 2020
Autophagy is an important intracellular process that supports cell death and survival. Oncogenesis is associated with a change in the AKT/mTOR signaling pathway status.
Liudmila V. Spirina, Sventlana Yu. Chizhevskaya, Irina V. Kondakova, Nataliya V. Tarasenko   +3 more
doaj   +1 more source

RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. [PDF]

, 2013
ObjectiveTo determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy.BackgroundRAS mutation has been reported ...
Aloia, Thomas A, Andreou, Andreas, Chen, Su S, Curley, Steven A, Kopetz, Scott E, Maru, Dipen M, Shindoh, Junichi, Vauthey, Jean-Nicolas, Zimmitti, Giuseppe   +8 more
core   +1 more source

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes [PDF]

, 2022
Alessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, Dario de Biase, Francesca Giunchi, Arianna Palladini, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni   +8 more
openalex   +1 more source

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas [PDF]

Frontiers in Oncology, 2018
Low-grade gliomas (LGG) are the most common central nervous system tumors in children. Prognosis depends on complete surgical resection. For patients not amenable of gross total resection (GTR) new approaches are needed. The BRAF mutation V600E is critical for the pathogenesis of pediatric gliomas and specific inhibitors of the mutated protein, such as
Francesca Del Bufalo, Giulia Ceglie, Antonella Cacchione, Iside Alessi, Giovanna Stefania Colafati, Andrea Carai, Francesca Diomedi-Camassei, Emmanuel De Billy, Emanuele Agolini, Angela Mastronuzzi, Franco Locatelli, Franco Locatelli   +11 more
openaire   +3 more sources

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis

Advanced Science, EarlyView.
This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer, Thomas Albrecht, Alphonse Charbel, Michael T. Dill, Carsten Sticht, Carolina De La Torre, Stefan Pusch, Arianeb Mehrabi, Kai Breuhahn, Junfang Ji, Peter Schirmacher, Benjamin Goeppert, Stephanie Roessler   +21 more
wiley   +1 more source

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

OncoImmunology, 2018
Background: Approximately 50% of melanomas harbor BRAF mutations. Treatment with BRAF +/− MEK inhibition is associated with favorable changes in the tumor microenvironment thus providing the rationale for combining targeted agents with immunotherapy ...
Meghan J. Mooradian, Alexandre Reuben, Peter A. Prieto, Mehlika Hazar-Rethinam, Dennie T. Frederick, Brandon Nadres, Adriano Piris, Vikram Juneja, Zachary A. Cooper, Arlene H. Sharpe, Ryan B. Corcoran, Keith T. Flaherty, Donald P. Lawrence, Jennifer A. Wargo, Ryan J. Sullivan   +14 more
doaj   +1 more source

Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease [PDF]

, 2022
Christopher Cronin, Ronan Andrew McLaughlin, Louise Lane, Francesca M. Brett, Michael Jansen, Niamh Bermingham, Gerald Wyse, Liam Grogan, Patrick G. Morris, Séamus O’Reilly   +9 more
openalex   +1 more source

Foundation Model‐Enabled Multimodal Deep Learning for Prognostic Prediction in Colorectal Cancer with Incomplete Modalities: A Multi‐Institutional Retrospective Study

Advanced Science, EarlyView.
FLARE, a multimodal AI framework, combines pathology slides, radiology scans, and clinical reports to predict colorectal cancer outcomes, even when some tests are missing. Evaluated retrospectively in 1679 patients from four medical centers, it consistently achieved the best prognostic accuracy and clearly separated high‐ and low‐risk groups.
Linhao Qu, Chengsheng Zhang, Yingyong Hou, Feng Tang, Weiqi Sheng, Dan Huang, Zhijian Song   +6 more
wiley   +1 more source